Cell-Free DNA Fragmentomes in the Diagnostic Evaluation of Patients With Symptoms Suggestive of Lung Cancer-Reference-Cited by-同舟云学术

Cell-Free DNA Fragmentomes in the Diagnostic Evaluation of Patients With Symptoms Suggestive of Lung Cancer

Published:2023-10 Issue:4 Volume:164 Page:1019-1027
ISSN:0012-3692
Container-title:CHEST
language:en
Short-container-title:CHEST

Author:

Leal Alessandro I.C.^ORCID,Mathios Dimitrios,Jakubowski Debbie,Johansen Jakob S.,Lau Anna^ORCID,Wu Tony,Cristiano Stephen,Medina Jamie E.^ORCID,Phallen Jillian,Bruhm Daniel C.,Carey Jacob,Dracopoli Nicholas C.,Bojesen Stig E.,Scharpf Robert B.^ORCID,Velculescu Victor E.,Vachani Anil^ORCID,Bach Peter B.

Publisher

Elsevier BV

Subject

Cardiology and Cardiovascular Medicine,Critical Care and Intensive Care Medicine,Pulmonary and Respiratory Medicine

Reference45 articles.

1. Delays in the diagnosis of lung cancer;Ellis;J Thorac Dis,2011

2. Symptoms and other factors associated with time to diagnosis and stage of lung cancer: a prospective cohort study;Walter;Br J Cancer,2015

3. Typical time to treatment of patients with lung cancer in a multisite, US-based study;Vidaver;J Oncol Pract,2016

4. Timeliness of access to lung cancer diagnosis and treatment: a scoping literature review;Jacobsen;Lung Cancer,2017

5. How long is too long? A scoping review of health system delays in lung cancer;Malalasekera;Eur Respir Rev,2018

Cited by 5 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Harnessing the potential of genomic characterization of mutational profiles to improve early diagnosis of lung cancer;Expert Review of Molecular Diagnostics;2024-09-12

2. COUNTERPOINT: Liquid Markers for Risk Stratification of Pulmonary Nodules, Ready for Prime Time? Not Yet!;CHEST Pulmonary;2024-09

3. Liquid Biopsies Based on Cell-Free DNA Integrity as a Biomarker for Cancer Diagnosis: A Meta-Analysis;Diagnostics;2024-07-09

4. Next-generation sequencing impact on cancer care: applications, challenges, and future directions;Frontiers in Genetics;2024-07-09

5. Frameshift mutations in peripheral blood as a biomarker for surveillance of Lynch syndrome;JNCI: Journal of the National Cancer Institute;2024-03-11